We are live on ! Find out more
INKT icon

MiNK Therapeutics
INKT

21 hedge funds and large institutions have $565K invested in MiNK Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.21% → 0.2% (-0.01%)

11% less capital invested

Capital invested by funds: $632K → $565K (-$67.4K)

13% less funds holding

Funds holding: 24 → 21 (-3)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
21
Holders Change
-3
Holders Change %
-12.5%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$932
2
Northern Trust
Northern Trust
Illinois
+$252
3
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$170
4
JP Morgan Chase
JP Morgan Chase
New York
+$136
5
BlackRock
BlackRock
New York
+$102

Top Sellers

Rank Fund Capital Flow
1
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors
North Carolina
-$11.5K
2
TSS
Two Sigma Securities
New York
-$8.95K
3
Renaissance Technologies
Renaissance Technologies
New York
-$3.39K
4
UBS Group
UBS Group
Switzerland
-$2.29K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$1.27K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$163K – – –
LF
2
Longbow Finance
Switzerland
$116K – – –
Renaissance Technologies
3
Renaissance Technologies
New York
$70.9K -$3.39K -498 -5%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$67K -$1.27K -187 -2%
BlackRock
5
BlackRock
New York
$61.5K +$102 +15 +0.2%
HighTower Advisors
6
HighTower Advisors
Illinois
$35.3K -$714 -105 -2%
State Street
7
State Street
Massachusetts
$17.8K – – –
GWM
8
Greenwich Wealth Management
Connecticut
$8K – – –
Northern Trust
9
Northern Trust
Illinois
$7.97K +$252 +37 +3%
Wells Fargo
10
Wells Fargo
California
$7.02K -$306 -45 -4%
TRCT
11
Tower Research Capital (TRC)
New York
$3.76K +$932 +137 +34%
UBS Group
12
UBS Group
Switzerland
$1.98K -$2.29K -336 -54%
Bank of America
13
Bank of America
North Carolina
$1.42K – – –
C
14
Covestor
United Kingdom
$1K – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$918 -$75 -11 -8%
Morgan Stanley
16
Morgan Stanley
New York
$233 -$7 -1 -3%
JP Morgan Chase
17
JP Morgan Chase
New York
$227 +$136 +20 +154%
BNP Paribas Financial Markets
18
BNP Paribas Financial Markets
France
$172 +$170 +25 New
Northwestern Mutual Wealth Management
19
Northwestern Mutual Wealth Management
Wisconsin
$132 – – –
GPFA
20
Game Plan Financial Advisors
Ohio
$116 – – –
KFI
21
Key Financial Inc
Pennsylvania
$30 – – –
AF
22
Allworth Financial
California
$3 – – –
Fidelity Investments
23
Fidelity Investments
Massachusetts
$1 – – –
CAPTRUST Financial Advisors
24
CAPTRUST Financial Advisors
North Carolina
– -$11.5K -1,532 Closed
TSS
25
Two Sigma Securities
New York
– -$8.95K -1,194 Closed
1
2

INKT Hedge Fund Activity: Q4 2024 in Review

21 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in MiNK Therapeutics (INKT) for Q4 2024, worth a combined $565K — down 11% from $632K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of INKT and 1 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Tower Research Capital (TRC), adding an estimated $932. The largest seller was CAPTRUST Financial Advisors, exiting entirely with an estimated $11.5K sold.

  • 21 institutional investors held MiNK Therapeutics (INKT) as of Q4 2024, down from 24 in Q3 2024.
  • Funds reported $565K of MiNK Therapeutics stock for Q4 2024, down 11% quarter-over-quarter.
  • 1 fund opened new MiNK Therapeutics positions in Q4 2024 and 4 closed out, a net change of -3 holders.
  • The largest MiNK Therapeutics buyer in Q4 2024 was Tower Research Capital (TRC), an estimated $932 added.
  • The largest MiNK Therapeutics seller in Q4 2024 was CAPTRUST Financial Advisors, an estimated $11.5K sold.

Based on aggregated 13F filings for Q4 2024.